Key facts
- Notable investors include TiVenture.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Inhalis Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Inhalis Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Inhalis Therapeutics
Developer of inhaled treatment technology designed to improve patients' lives.The company focuses on developing novel inhalation technologies for diseases like Idiopathic Pulmonary Fibrosis and other serious conditions, utilizing a combination of solid science and industry-leading delivery systems, enabling physicians to improve patient outcomes with safe and effective treatments.
- Sector
- Healthcare
- HQ
- Lugano, Switzerland
- Founded
- 2023
- Employees
- 5
- Website
- inhalis.com/
- Ownership
- Privately Held (backing)
Inhalis Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Inhalis Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Inhalis Therapeutics in its N-PORT filings yet. We sweep new filings monthly.